WARREN, N.J. - Tevogen Bio, a clinical-stage immunotherapy company, announced the initiation of its pre-clinical efforts for TVGN 920, a potential treatment targeting Human Papillomavirus (HPV). The company, which specializes in T cell therapeutics, has utilized its proprietary ExacTcell technology to identify cytotoxic T cell (CTL) targets within the HPV genome. This marks the start of Tevogen's oncology pipeline aimed at addressing HPV-related cancers.
HPV is a significant global health concern, with 5.5 million women contracting HPV strains 16/18 annually, leading to 200,000 diagnoses of high-grade dysplasia each year. Tevogen's approach involves training CTLs to detect and target specific proteins of the HPV virus, a method that has previously shown promise in their SARS-CoV-2-specific CTLs.
The company has partnered with Microsoft to leverage artificial intelligence and cloud technologies, which has expedited the target identification process for their oncology product. "By leveraging Microsoft’s cutting-edge AI and cloud technologies, we’re able to accelerate our target identification and pre-clinical processes in ways that weren’t previously possible," said Mittul Mehta, Chief Information Officer and Head of Tevogen.AI.
Dr. Neal Flomenberg, Chief Scientific Officer at Tevogen Bio, expressed confidence in the adaptability of their ExacTcell technology, which has been effective in other viral targets, to the HPV-specific CTL treatment.
Ryan Saadi, Founder and CEO of Tevogen Bio, commented on the broader implications of their work, noting the significant healthcare costs in the U.S. and the potential impact innovative treatments like TVGN 920 could have on economic prosperity and patient affordability.
Tevogen Bio focuses on developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious diseases and cancers. The company has reported positive safety data from its proof-of-concept clinical trial and owns key intellectual property assets, including three granted patents and numerous pending patents.
This announcement is based on a press release statement from Tevogen Bio. The company's forward-looking statements involve certain risks and uncertainties, including the need for additional capital and the challenges of rapid technological developments. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates.
In other recent news, Microsoft Corporation (NASDAQ:MSFT) reported strong financial results in its Q1 FY2025 earnings call, highlighting significant growth in its cloud and AI sectors. Revenue for the quarter stood at $65.6 billion, a 16% increase from the previous year, and earnings per share grew by 10% to $3.30. Microsoft Cloud was a standout, generating over $38.9 billion in revenue, a 22% year-on-year increase. The company's AI business is also on a promising trajectory, projected to exceed a $10 billion annual run rate in the upcoming quarter.
On the downside, non-AI Azure growth saw a sequential decline of approximately 1 point and on-premises server revenue decreased by 1%. Despite these challenges, Azure's revenue grew by 33%, with AI services contributing significantly. The company returned $9 billion to shareholders through dividends and share repurchases.
Looking ahead, Microsoft anticipates continued strong demand, projecting commercial bookings to grow 30% in Q2, and Azure revenue is projected to grow by 31-32%. The company maintains a disciplined focus on cost management while investing in long-term growth opportunities. These are some of the recent developments concerning Microsoft Corporation.
InvestingPro Insights
As Tevogen Bio partners with Microsoft to leverage AI and cloud technologies for its oncology pipeline, it's worth examining Microsoft's financial position and market performance. According to InvestingPro data, Microsoft boasts a substantial market capitalization of $3.05 trillion, reflecting its dominant position in the tech industry.
Microsoft's revenue growth remains robust, with a 16.44% increase over the last twelve months, reaching $254.19 billion. This growth aligns well with Tevogen Bio's strategic partnership, as Microsoft's strong financial performance suggests it can continue investing in and supporting innovative healthcare technologies.
InvestingPro Tips highlight Microsoft's strength as a dividend payer, having raised its dividend for 19 consecutive years and maintained payments for 22 years. This demonstrates the company's financial stability and commitment to shareholder returns, which could be reassuring for partners like Tevogen Bio.
Another relevant InvestingPro Tip notes that Microsoft is a prominent player in the software industry, which is crucial for its AI and cloud capabilities that Tevogen Bio is leveraging. The company's strong market position and technological expertise make it a valuable partner for biotech firms pursuing innovative treatments.
For investors interested in Microsoft's role in healthcare innovation, InvestingPro offers 11 additional tips that provide further insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.